Thermo Fisher Scientific Inc. (TMO) price prediction
We do not issue point price predictions. Instead, our analysis anchors TMO to a composite fair-value range of $384–$619 (midpoint $501, current price $474) and a probability-weighted bull/base/bear distribution that resolves to a weighted price target of $500.89 and a weighted return of +5.6%.
Bull, base and bear price targets
Bull case (probability 20%): target $618.78, implied return +30.4%. Base case (probability 60%): target $500.89, implied return +5.6%. Bear case (probability 20%): target $384.14, implied return -19.0%.
These are not points-on-a-chart guesses. Each scenario is built from explicit revenue, margin, and capital-allocation assumptions, and discounted at 8.45%. Probability weights are calibrated to Thermo Fisher Scientific Inc.'s mature compounder archetype — the bull tail is fatter for hyper-growth names, thinner for mature compounders, and inverted for cyclicals near peak.
Probability-weighted expected return
Folding bull/base/bear into a single weighted view, TMO's probability-weighted price target is $500.89 and the weighted return is +5.6%. The asymmetry signal — the gap between weighted return and base-case return — is Probability-weighted expected value of $478.69 closely aligns with current trading levels, supporting a neutral stance..
Asymmetry matters more than the headline return. A 10% expected return with a 30%-bear/15%-bull dispersion is a different bet than a 10% expected return with a 10%-bear/12%-bull dispersion. The full report walks through both for TMO.
What our forecast deliberately does not do
We do not publish twelve monthly price targets across a calendar year, we do not back-test indicators on past prices, and we do not anchor any number to "analyst consensus" — the consensus is a useful sanity check, not a target. If our composite fair value differs from the analyst consensus by more than 30%, the full report runs a consensus-divergence diagnostic instead of silently revising toward the crowd.
What we do publish: the 5×5 Ke-versus-terminal-growth sensitivity matrix, five formal stress tests with quantified fair-value impact, an earnings decision tree if reporting is within 60 days, and explicit position-management checkpoints. Together those answer "what if my view is wrong?" — a more useful question for an investor than "what's the price next month?".
How to use this for TMO
Anchor on the fair-value range ($384–$619), size against the bull/base/bear distribution, and define a kill-scenario list before entry. Our current rating for TMO is Hold; rating-band changes are the trigger for re-sizing, not for trading the noise around them.
For the canonical version of this answer — including the sensitivity matrix, scorecard, and full assumption ledger — see the full report at /stocks/tmo/analysis.
Frequently asked questions
What is the price prediction for TMO?
We anchor TMO to a fair-value range of $384–$619, with a midpoint of $501. The probability-weighted price target is $500.89 (weighted return +5.6%). We do not issue single-point price predictions.
What is the bull-case target for TMO?
The bull case (probability 20%) targets $618.78, an implied return of +30.4%.
What is the bear-case target for TMO?
The bear case (probability 20%) targets $384.14, an implied return of -19.0%.
Do you publish a 12-month TMO price target?
No. We publish a fair-value range, a bull/base/bear distribution with explicit probabilities, and a probability-weighted expected return — not a single 12-month point.
Research for educational purposes. Not personalised investment advice. See the full TMO report for the canonical evidence.